More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features
Marko Lucijanic,Renata Huzjan Korunic,Martina Sedinic,Rajko Kusec,Vlatko Pejsa
DOI: https://doi.org/10.2147/TCRM.S323749
2021-09-24
Therapeutics and Clinical Risk Management
Abstract:Marko Lucijanic, 1, 2 Renata Huzjan Korunic, 2, 3 Martina Sedinic, 1 Rajko Kusec, 1, 2 Vlatko Pejsa 1, 2 1 Hematology Department, University Hospital Dubrava, Zagreb, Croatia; 2 University of Zagreb School of Medicine, Zagreb, Croatia; 3 Radiology Department, University Hospital Dubrava, Zagreb, Croatia Correspondence: Marko Lucijanic Hematology Department, University Hospital Dubrava, Av. Gojka Suska 6, Zagreb, 10000, Croatia Email Introduction: Cancer-induced cachexia is associated with poor prognosis in patients with non-Hodgkin lymphoma, but it is unknown how and to what extent curable lymphoma treatments affect the musculoskeletal system. Patients and Methods: We retrospectively analyzed 104 newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients with unfavorable disease features treated with the R-DA-EPOCH regimen. Psoas muscle area (PMA) measured at L3 vertebra level was compared between staging (pre-therapy) and revision (end of treatment) computerized tomography (CT) scans. Results: Small but significant decline in PMA was observed during the immunochemotherapy period (average loss 5%; P =0.016) with 57.7% of patients experiencing muscle loss. Higher body surface area (OR=17.98 for each m 2 ; P =0.034), number of cycles with dose reduction (OR=2.86 for each cycle; P =0.039) and worse response to therapy (OR=3.09 for each response category; P =0.052) were recognized as independent contributors to the PMA loss in multivariate analysis. One quarter of patients had more pronounced PMA loss (≥ 21%), which was associated with significantly worse overall and progression-free survival. Both ≥ 21% PMA loss and non-achieving response to therapy remained independently associated with inferior OS (PMA loss HR=2.98; P =0.016 and achieving response HR=0.04; P < 0.001) and PFS (PMA loss HR=3.16; P =0.005 and achieving response HR=0.08; P =0.001) in multivariate analyses. Discussion: Muscle loss occurs in approximately half of newly diagnosed DLBCL patients with unfavorable disease features during R-DA-EPOCH immunochemotherapy. If pronounced, this is associated with worse clinical outcomes irrespectively of achieved response to therapy. Muscle loss seems to be mostly affected by the efficacy and tolerability of the regimen. Keywords: diffuse large B-cell lymphoma, sarcopenia, psoas muscle, R-DA-EPOCH, survival Patients with aggressive lymphoid malignancies receive intensive immunochemotherapeutic therapies that result with a cure in a majority of patients. Our paper is the first to provide an overview of the extent and clinical associations of muscle loss during therapy with one of the standard immunochemotherapy regimens (R-DA-EPOCH) for aggressive diffuse large B-cell lymphoma with unfavorable disease features. Our data show that muscle loss is common in these patients but detrimental only if very pronounced. Factors that affect muscle loss are mostly related to immunochemotherapy and not disease features prior to therapy per se. Diffuse large B-cell lymphoma (DLBCL) is the most common subset of aggressive non-Hodgkin lymphomas (NHL). It is curable in a majority of newly diagnosed patients using the R-CHOP immunochemotherapy regimen which is a current standard of care. Still, a substantial proportion of DLBCL patients with very aggressive and poor prognostic disease features have unsatisfactory outcomes when treated with R-CHOP regimen and these patients might benefit from more intensive therapeutic approaches. 1 Although no significant improvement could be demonstrated for the R-DA-EPOCH regimen in a randomized controlled trial in comparison to R-CHOP in unselected DLBCL patients, 2 a number studies reported improved outcomes with the R-DA-EPOCH regimen in patients with unfavorable disease features. 3–5 Hematologic malignancies are often characterized by presence of constitutional symptoms driven by high cytokine activity like involuntary body weight loss and profound night sweating. Cancer-induced cachexia, ie loss of muscle and fat tissue, and sarcopenia, ie loss of skeletal muscle tissue, present at baseline have been associated with more advanced disease features, functional impairment and inferior prognosis in patients with various malignancies, including Hodgkin lymphoma and NHL patients. 6–8 Loss of skeletal muscle mass during chemotherapy was shown to have negative prognostic implications in patients with gastrointestinal malignancies. 9–11 It is unknown, however, how and to what extent curable lymphoma treatments affect the musculoskeletal system and might the -Abstract Truncated-
health care sciences & services